ArticleFrontiers in oncology2026
Dendrobine inhibits anaplastic thyroid cancer progression by targeting the JAK-STAT3 pathway.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the antitumor effects of dendrobine on ATC cells and its mechanism targeting the JAK-STAT3 pathway. Methods: Human ATC cell lines (CAL-62 and 8505C) were treated with dendrobine (DEM). Detect cell viability, cell proliferation, cell apoptosis, cell migration and invasion. The expressions of E-cad, N-cad and Vim were detected by IF. JAK1, JAK2, STAT3 and their phosphorylated forms were quantified by WB. To probe pathway reversibility, cells were pretreated with IL-6 (20 ng/mL) or STAT3-siRNA before dendrobine exposure. Results: Dendrobine reduced the viability of CAL-62 and 8505C cells, with 5 μM dendrobine achieving the most pronounced inhibition ( Conclusion: Dendrobine exerts antitumor effects in ATC by targeting the JAK-STAT3 pathway, providing a promising therapeutic candidate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.